Tools to Define the Melanoma-associated Immunopeptidome

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2017 Jul 30

PMID 28755382

Citations 5

Authors

Eva Braunlein

Angela M Krackhardt

Affiliations

Soon will be listed here.

Abstract

Immunotherapies have been traditionally applied in malignant melanoma, which represent one of the most immunogenic tumours. Recently, immune checkpoint modulation has shown high therapeutic efficacy and may provide long-term survival in a significant proportion of affected patients. T cells are the major players in tumour rejection and recognize tumour cells predominantly in an MHC-dependent way. The immunopeptidome comprises the peptide repertoire presented by MHC class I and II molecules on the surface of the body's cells including tumour cells. To understand characteristics of suitable rejection antigens as well as respective effective T-cell responses, determination of the immunopeptidome is of utmost importance. Suitable rejection antigens need to be further characterized and validated not only to systematically improve current therapeutic approaches, but also to develop individualized treatment options. In this review, we report on current tools to explore the immunopeptidome in human melanoma and discuss current understanding and future developments to specifically detect and select those antigens that may be most relevant and promising for effective tumour rejection.

Citing Articles

Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.

Podaza E, Carri I, Aris M, Von Euw E, Bravo A, Blanco P Front Immunol. 2020; 11:1147.

PMID: 32582212 PMC: 7290006. DOI: 10.3389/fimmu.2020.01147.

An Immunological Glance on Pancreatic Ductal Adenocarcinoma.

Melzer M, Arnold F, Stifter K, Zengerling F, Azoitei N, Seufferlein T Int J Mol Sci. 2020; 21(9).

PMID: 32397303 PMC: 7246613. DOI: 10.3390/ijms21093345.

The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.

Vizcaino J, Kubiniok P, Kovalchik K, Ma Q, Duquette J, Mongrain I Mol Cell Proteomics. 2019; 19(1):31-49.

PMID: 31744855 PMC: 6944237. DOI: 10.1074/mcp.R119.001743.

New tools for MHC research from machine learning and predictive algorithms to the tumour immunopeptidome.

Altmann D Immunology. 2018; 154(3):329-330.

PMID: 29902342 PMC: 6002226. DOI: 10.1111/imm.12956.

Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol J, Zitvogel L, Kroemer G Oncoimmunology. 2017; 6(12):e1398878.

PMID: 29209575 PMC: 5706602. DOI: 10.1080/2162402X.2017.1398878.

References

Reeves E, James E . Antigen processing and immune regulation in the response to tumours. Immunology. 2016; 150(1):16-24. PMC: 5341504. DOI: 10.1111/imm.12675. View

Sharon E, Sibener L, Battle A, Fraser H, Garcia K, Pritchard J . Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat Genet. 2016; 48(9):995-1002. PMC: 5010864. DOI: 10.1038/ng.3625. View

Coulie P, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C . A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180(1):35-42. PMC: 2191574. DOI: 10.1084/jem.180.1.35. View

Wang R, Wang X, ATWOOD A, Topalian S, Rosenberg S . Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999; 284(5418):1351-4. DOI: 10.1126/science.284.5418.1351. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Maczek C, Berger T, Schuler-Thurner B, Schultz E, Hamann A, Dunbar P . Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. Int J Cancer. 2005; 115(3):450-5. DOI: 10.1002/ijc.20901. View

Anderson K, Stromnes I, Greenberg P . Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017; 31(3):311-325. PMC: 5423788. DOI: 10.1016/j.ccell.2017.02.008. View

Balar A, Weber J . PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017; 66(5):551-564. PMC: 11028560. DOI: 10.1007/s00262-017-1954-6. View

Storkus W, Zeh 3rd H, Maeurer M, Salter R, Lotze M . Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol. 1993; 151(7):3719-27. View

10.

SUMNER W, Foraker A . Spontaneous regression of human melanoma: clinical and experimental studies. Cancer. 1960; 13:79-81. DOI: 10.1002/1097-0142(196001/02)13:1<79::aid-cncr2820130115>3.0.co;2-4. View

11.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

12.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

13.

Hedrick S, Cohen D, Nielsen E, Davis M . Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature. 1984; 308(5955):149-53. DOI: 10.1038/308149a0. View

14.

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217-221. PMC: 5577644. DOI: 10.1038/nature22991. View

15.

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, De Plaen E . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995; 269(5228):1281-4. DOI: 10.1126/science.7652577. View

16.

Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A . Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A. 2010; 107(44):18769-76. PMC: 2973870. DOI: 10.1073/pnas.1008501107. View

17.

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

18.

Tran E, Robbins P, Lu Y, Prickett T, Gartner J, Jia L . T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23):2255-2262. PMC: 5178827. DOI: 10.1056/NEJMoa1609279. View

19.

Garcia K, Adams J, Feng D, Ely L . The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol. 2009; 10(2):143-7. PMC: 3982143. DOI: 10.1038/ni.f.219. View

20.

Vita R, Overton J, Greenbaum J, Ponomarenko J, Clark J, Cantrell J . The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2014; 43(Database issue):D405-12. PMC: 4384014. DOI: 10.1093/nar/gku938. View